Cargando…
Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis
OBJECTIVES: Cardiac magnetic resonance (CMR) was used to investigate the extracellular compartment and myocardial fibrosis in patients with aortic stenosis, as well as their association with other measures of left ventricular decompensation and mortality. BACKGROUND: Progressive myocardial fibrosis...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683736/ https://www.ncbi.nlm.nih.gov/pubmed/28017384 http://dx.doi.org/10.1016/j.jcmg.2016.10.007 |
_version_ | 1783278346252058624 |
---|---|
author | Chin, Calvin W.L. Everett, Russell J. Kwiecinski, Jacek Vesey, Alex T. Yeung, Emily Esson, Gavin Jenkins, William Koo, Maria Mirsadraee, Saeed White, Audrey C. Japp, Alan G. Prasad, Sanjay K. Semple, Scott Newby, David E. Dweck, Marc R. |
author_facet | Chin, Calvin W.L. Everett, Russell J. Kwiecinski, Jacek Vesey, Alex T. Yeung, Emily Esson, Gavin Jenkins, William Koo, Maria Mirsadraee, Saeed White, Audrey C. Japp, Alan G. Prasad, Sanjay K. Semple, Scott Newby, David E. Dweck, Marc R. |
author_sort | Chin, Calvin W.L. |
collection | PubMed |
description | OBJECTIVES: Cardiac magnetic resonance (CMR) was used to investigate the extracellular compartment and myocardial fibrosis in patients with aortic stenosis, as well as their association with other measures of left ventricular decompensation and mortality. BACKGROUND: Progressive myocardial fibrosis drives the transition from hypertrophy to heart failure in aortic stenosis. Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis. METHODS: In a prospective observational cohort study, 203 subjects (166 with aortic stenosis [69 years; 69% male]; 37 healthy volunteers [68 years; 65% male]) underwent comprehensive phenotypic characterization with clinical imaging and biomarker evaluation. On CMR, we quantified the total extracellular volume of the myocardium indexed to body surface area (iECV). The iECV upper limit of normal from the control group (22.5 ml/m(2)) was used to define extracellular compartment expansion. Areas of replacement mid-wall LGE were also identified. All-cause mortality was determined during 2.9 ± 0.8 years of follow up. RESULTS: iECV demonstrated a good correlation with diffuse histological fibrosis on myocardial biopsies (r = 0.87; p < 0.001; n = 11) and was increased in patients with aortic stenosis (23.6 ± 7.2 ml/m(2) vs. 16.1 ± 3.2 ml/m(2) in control subjects; p < 0.001). iECV was used together with LGE to categorize patients with normal myocardium (iECV <22.5 ml/m(2); 51% of patients), extracellular expansion (iECV ≥22.5 ml/m(2); 22%), and replacement fibrosis (presence of mid-wall LGE, 27%). There was evidence of increasing hypertrophy, myocardial injury, diastolic dysfunction, and longitudinal systolic dysfunction consistent with progressive left ventricular decompensation (all p < 0.05) across these groups. Moreover, this categorization was of prognostic value with stepwise increases in unadjusted all-cause mortality (8 deaths/1,000 patient-years vs. 36 deaths/1,000 patient-years vs. 71 deaths/1,000 patient-years, respectively; p = 0.009). CONCLUSIONS: CMR detects ventricular decompensation in aortic stenosis through the identification of myocardial extracellular expansion and replacement fibrosis. This holds major promise in tracking myocardial health in valve disease and for optimizing the timing of valve replacement. (The Role of Myocardial Fibrosis in Patients With Aortic Stenosis; NCT01755936) |
format | Online Article Text |
id | pubmed-5683736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-56837362017-11-20 Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis Chin, Calvin W.L. Everett, Russell J. Kwiecinski, Jacek Vesey, Alex T. Yeung, Emily Esson, Gavin Jenkins, William Koo, Maria Mirsadraee, Saeed White, Audrey C. Japp, Alan G. Prasad, Sanjay K. Semple, Scott Newby, David E. Dweck, Marc R. JACC Cardiovasc Imaging Article OBJECTIVES: Cardiac magnetic resonance (CMR) was used to investigate the extracellular compartment and myocardial fibrosis in patients with aortic stenosis, as well as their association with other measures of left ventricular decompensation and mortality. BACKGROUND: Progressive myocardial fibrosis drives the transition from hypertrophy to heart failure in aortic stenosis. Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis. METHODS: In a prospective observational cohort study, 203 subjects (166 with aortic stenosis [69 years; 69% male]; 37 healthy volunteers [68 years; 65% male]) underwent comprehensive phenotypic characterization with clinical imaging and biomarker evaluation. On CMR, we quantified the total extracellular volume of the myocardium indexed to body surface area (iECV). The iECV upper limit of normal from the control group (22.5 ml/m(2)) was used to define extracellular compartment expansion. Areas of replacement mid-wall LGE were also identified. All-cause mortality was determined during 2.9 ± 0.8 years of follow up. RESULTS: iECV demonstrated a good correlation with diffuse histological fibrosis on myocardial biopsies (r = 0.87; p < 0.001; n = 11) and was increased in patients with aortic stenosis (23.6 ± 7.2 ml/m(2) vs. 16.1 ± 3.2 ml/m(2) in control subjects; p < 0.001). iECV was used together with LGE to categorize patients with normal myocardium (iECV <22.5 ml/m(2); 51% of patients), extracellular expansion (iECV ≥22.5 ml/m(2); 22%), and replacement fibrosis (presence of mid-wall LGE, 27%). There was evidence of increasing hypertrophy, myocardial injury, diastolic dysfunction, and longitudinal systolic dysfunction consistent with progressive left ventricular decompensation (all p < 0.05) across these groups. Moreover, this categorization was of prognostic value with stepwise increases in unadjusted all-cause mortality (8 deaths/1,000 patient-years vs. 36 deaths/1,000 patient-years vs. 71 deaths/1,000 patient-years, respectively; p = 0.009). CONCLUSIONS: CMR detects ventricular decompensation in aortic stenosis through the identification of myocardial extracellular expansion and replacement fibrosis. This holds major promise in tracking myocardial health in valve disease and for optimizing the timing of valve replacement. (The Role of Myocardial Fibrosis in Patients With Aortic Stenosis; NCT01755936) Elsevier 2017-11 /pmc/articles/PMC5683736/ /pubmed/28017384 http://dx.doi.org/10.1016/j.jcmg.2016.10.007 Text en © 2017 Elsevier Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chin, Calvin W.L. Everett, Russell J. Kwiecinski, Jacek Vesey, Alex T. Yeung, Emily Esson, Gavin Jenkins, William Koo, Maria Mirsadraee, Saeed White, Audrey C. Japp, Alan G. Prasad, Sanjay K. Semple, Scott Newby, David E. Dweck, Marc R. Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis |
title | Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis |
title_full | Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis |
title_fullStr | Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis |
title_full_unstemmed | Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis |
title_short | Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis |
title_sort | myocardial fibrosis and cardiac decompensation in aortic stenosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683736/ https://www.ncbi.nlm.nih.gov/pubmed/28017384 http://dx.doi.org/10.1016/j.jcmg.2016.10.007 |
work_keys_str_mv | AT chincalvinwl myocardialfibrosisandcardiacdecompensationinaorticstenosis AT everettrussellj myocardialfibrosisandcardiacdecompensationinaorticstenosis AT kwiecinskijacek myocardialfibrosisandcardiacdecompensationinaorticstenosis AT veseyalext myocardialfibrosisandcardiacdecompensationinaorticstenosis AT yeungemily myocardialfibrosisandcardiacdecompensationinaorticstenosis AT essongavin myocardialfibrosisandcardiacdecompensationinaorticstenosis AT jenkinswilliam myocardialfibrosisandcardiacdecompensationinaorticstenosis AT koomaria myocardialfibrosisandcardiacdecompensationinaorticstenosis AT mirsadraeesaeed myocardialfibrosisandcardiacdecompensationinaorticstenosis AT whiteaudreyc myocardialfibrosisandcardiacdecompensationinaorticstenosis AT jappalang myocardialfibrosisandcardiacdecompensationinaorticstenosis AT prasadsanjayk myocardialfibrosisandcardiacdecompensationinaorticstenosis AT semplescott myocardialfibrosisandcardiacdecompensationinaorticstenosis AT newbydavide myocardialfibrosisandcardiacdecompensationinaorticstenosis AT dweckmarcr myocardialfibrosisandcardiacdecompensationinaorticstenosis |